Paul Phillips, MD
Ophthalmology · Flemington, NJNPI 1073538153
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,000 of the $14,180 with a category attached, or 63.5%. Rxsight Inc accounts for 74.0% of it on its own, with 26 other manufacturers making up the rest. Among ophthalmology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 167 payments — averaging $84.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$10K
- Alcon$1K
- NEW World Medical,inc.$387
- Johnson & Johnson Surgical Vision, Inc.$375
- Dompe US, Inc.$375
- Bausch & Lomb Americas Inc.$138
- plus $964 from 21 others
What the payments were for
- Consulting fees$9,00063%
- Speaking & faculty fees$460%
- Food & beverage$5,13536%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 32 | $10,497 |
| Alcon | 49 | $1,445 |
| NEW World Medical,inc. | 4 | $387 |
| Johnson & Johnson Surgical Vision, Inc. | 10 | $375 |
| Dompe US, Inc. | 14 | $375 |
| Bausch & Lomb Americas Inc. | 9 | $138 |
| GSK | 1 | $125 |
| Tarsus Pharmaceuticals, Inc. | 6 | $113 |
| Mallinckrodt Hospital Products Inc. | 5 | $74 |
| Oyster Point Pharma, Inc. | 4 | $62 |
| Astellas Pharma US Inc | 4 | $60 |
| Ocular Therapeutix, Inc. | 3 | $60 |
| Amgen(2 entities) | 4 | $59 |
| Coopervision Inc. | 1 | $52 |
| Biotissue Holdings Inc. | 3 | $51 |
| Alimera Sciences, Inc. | 1 | $46 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $42 |
| Harrow Eye, LLC | 2 | $37 |
| Sun Pharmaceutical Industries Inc. | 2 | $31 |
| Novartis | 2 | $28 |
| AbbVie(2 entities) | 2 | $28 |
| Sandoz | 1 | $19 |
| ANI Pharmaceuticals, Inc. | 1 | $18 |
| Lumibird Medical Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $15 |
| Kala Pharmaceuticals, Inc. | 1 | $15 |
| Glaukos Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$9,554
- RXSIGHT INJECTOR CARTRIDGE$9,554
- RXSIGHT INJECTOR HANDPIECE$9,554
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$9,554
- LIGHT ADJUSTABLE LENS (LAL)$9,430
- Wavelight$250
- Ahmed Glaucoma Valve$250
- Kahook Dual Blade$250
- Clareon$149
- Streamline Surgical System$137
- SHINGRIX$125
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$125
- Oxervate$119
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$100
How this compares
$14,180 in reported general payments places this provider in the 90th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 31 | $42,560 |
| Prednisolone Acetate | 724 | $20,948 |
| XiidraLifitegrast | 14 | $12,140 |
| LumiganBimatoprost | 21 | $12,004 |
| CombiganBrimonidine Tartrate/Timolol | 26 | $9,015 |
| Cyclosporine | 15 | $8,979 |
| Latanoprost | 322 | $3,891 |
| Bromfenac Sodium | 18 | $3,467 |
| Loteprednol Etabonate | 15 | $2,330 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 87 | $1,885 |
| Ketorolac Tromethamine | 101 | $1,824 |
| Travoprost | 18 | $1,805 |
| Timolol Maleate | 40 | $1,677 |
| Brimonidine Tartrate | 28 | $852 |
| Pilocarpine Hcl | 11 | $812 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $28 | $63,57978 claims |
| Bausch & Lomb Americas Inc.Xiidra | $138 | $12,14014 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $42 | $2,33015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Flemington
- Jai ParekhWoodland Park$2M
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Cynthia MatossianPennington$655K
- Eric MannDover$604K
- Brett BieloryRutherford$477K
- Albert KhouriNewark$428K
- Robert FechtnerNewark$324K
- Rajen DesaiFreehold$311K
- Douglas GraysonIselin$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.